T2 Biosystems (NASDAQ: TTOO) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its peers? We will compare T2 Biosystems to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.
This is a breakdown of current ratings for T2 Biosystems and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|T2 Biosystems Competitors||172||1131||2469||89||2.64|
T2 Biosystems currently has a consensus target price of $6.83, suggesting a potential upside of 60.41%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 10.25%. Given T2 Biosystems’ higher possible upside, research analysts plainly believe T2 Biosystems is more favorable than its peers.
This table compares T2 Biosystems and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|T2 Biosystems Competitors||-127.39%||-36.85%||-10.55%|
Insider & Institutional Ownership
53.0% of T2 Biosystems shares are owned by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 38.7% of T2 Biosystems shares are owned by insiders. Comparatively, 11.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares T2 Biosystems and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|T2 Biosystems||$3.89 million||-$49.26 million||-2.17|
|T2 Biosystems Competitors||$827.23 million||$159.49 million||36.37|
T2 Biosystems’ peers have higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
T2 Biosystems has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, T2 Biosystems’ peers have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.
T2 Biosystems peers beat T2 Biosystems on 9 of the 12 factors compared.
T2 Biosystems Company Profile
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with our FREE daily email newsletter.